Lemur tyrosine kinase 2 (LMTK2) is a determinant of cell sensitivity to apoptosis by regulating the levels of the BCL2 family members.

[1]  Yufeng Shen,et al.  Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  E. F. da Cruz e Silva,et al.  Protein phosphatase 1 is a key player in nuclear events. , 2015, Cellular signalling.

[3]  N. Bradbury,et al.  Lemur Tyrosine Kinase 2, a novel target in prostate cancer therapy , 2015, Oncotarget.

[4]  J. Werner,et al.  Cancer cell-autonomous TRAIL-R signaling promotes KRAS-driven cancer progression, invasion, and metastasis. , 2015, Cancer cell.

[5]  A. Ashworth,et al.  Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathway , 2015, Oncotarget.

[6]  D. Lawrence,et al.  Opposing unfolded-protein-response signals converge on death receptor 5 to control apoptosis , 2014, Science.

[7]  H. Walczak,et al.  Getting TRAIL back on track for cancer therapy , 2014, Cell Death and Differentiation.

[8]  H. Walczak,et al.  TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells , 2014, Oncogene.

[9]  M. El-Bahrawy,et al.  Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1 , 2013, Cell Death and Differentiation.

[10]  A. Letai,et al.  Modulation of Mcl-1 sensitizes glioblastoma to TRAIL-induced apoptosis , 2013, Apoptosis.

[11]  M. Colombo,et al.  Smac mimetics induce inflammation and necrotic tumour cell death by modulating macrophage activity , 2013, Cell Death and Disease.

[12]  M. Fardilha,et al.  Protein Phosphatase 1γ Isoforms Linked Interactions in the Brain , 2013, Journal of Molecular Neuroscience.

[13]  M. Bolognesi,et al.  Dimeric Smac mimetics/IAP inhibitors as in vivo-active pro-apoptotic agents. Part II: Structural and biological characterization. , 2012, Bioorganic & medicinal chemistry.

[14]  Yoo Jin Jung,et al.  The transcriptional landscape and mutational profile of lung adenocarcinoma , 2012, Genome research.

[15]  Alessio Vagnoni,et al.  Cdk5/p35 phosphorylates lemur tyrosine kinase‐2 to regulate protein phosphatase‐1C phosphorylation and activity , 2012, Journal of neurochemistry.

[16]  Margarida Fardilha,et al.  Identification of the human testis protein phosphatase 1 interactome. , 2011, Biochemical pharmacology.

[17]  K. Lau,et al.  Lemur tyrosine kinase-2 signalling regulates kinesin light chain-2 phosphorylation and binding of Smad2 cargo , 2011, Oncogene.

[18]  S. Digumarthy,et al.  BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. , 2011, Cancer discovery.

[19]  F. Wandosell,et al.  Deconstructing GSK-3: The Fine Regulation of Its Activity , 2011, International journal of Alzheimer's disease.

[20]  G. Gores,et al.  A smac mimetic reduces TNF Related Apoptosis Inducing Ligand (TRAIL)‐induced invasion and metastasis of cholangiocarcinoma cells , 2010, Hepatology.

[21]  Paul McCullagh,et al.  Alterations in LMTK2, MSMB and HNF1B gene expression are associated with the development of prostate cancer , 2010, BMC Cancer.

[22]  M. Bolognesi,et al.  Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib , 2010, British Journal of Cancer.

[23]  A. Kibel.  Multiple newly identified loci associated with prostate cancer susceptibility , 2009 .

[24]  Ceri M. Wiggins,et al.  Apoptosis and autophagy: BIM as a mediator of tumour cell death in response to oncogene‐targeted therapeutics , 2009, The FEBS journal.

[25]  F. Buss,et al.  Overexpression of myosin VI in prostate cancer cells enhances PSA and VEGF secretion, but has no effect on endocytosis , 2009, Oncogene.

[26]  R. Herbst,et al.  To kill a tumor cell: the potential of proapoptotic receptor agonists. , 2008, The Journal of clinical investigation.

[27]  O. Ohara,et al.  BREK/LMTK2 is a myosin VI‐binding protein involved in endosomal membrane trafficking , 2008, Genes to cells : devoted to molecular & cellular mechanisms.

[28]  Ali Amin Al Olama,et al.  Multiple newly identified loci associated with prostate cancer susceptibility , 2008, Nature Genetics.

[29]  F. Buss,et al.  Myosin VI and its interacting protein LMTK2 regulate tubule formation and transport to the endocytic recycling compartment , 2007, Journal of Cell Science.

[30]  N. Yoshida,et al.  Azoospermia in mice with targeted disruption of the Brek/Lmtk2 (brain-enriched kinase/lemur tyrosine kinase 2) gene , 2006, Proceedings of the National Academy of Sciences.

[31]  D. Inta,et al.  Bim and Noxa Are Candidates to Mediate the Deleterious Effect of the NF-κB Subunit RelA in Cerebral Ischemia , 2006, The Journal of Neuroscience.

[32]  Andreas Untergasser,et al.  Preclinical Differentiation between Apparently Safe and Potentially Hepatotoxic Applications of TRAIL Either Alone or in Combination with Chemotherapeutic Drugs , 2006, Clinical Cancer Research.

[33]  Jun Qin,et al.  Erk Associates with and Primes GSK-3β for Its Inactivation Resulting in Upregulation of β-Catenin , 2005 .

[34]  G. Pigino,et al.  A novel CDK5‐dependent pathway for regulating GSK3 activity and kinesin‐driven motility in neurons , 2004, The EMBO journal.

[35]  Tadashi Yamamoto,et al.  Involvement of BREK, a serine/threonine kinase enriched in brain, in NGF signalling , 2004, Genes to cells : devoted to molecular & cellular mechanisms.

[36]  Eun Hee Kim,et al.  Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP , 2004, Oncogene.

[37]  C. Shaw,et al.  Identification of a Novel, Membrane-Associated Neuronal Kinase, Cyclin-Dependent Kinase 5/p35-Regulated Kinase , 2003, The Journal of Neuroscience.

[38]  Hong Wang,et al.  A Novel Transmembrane Ser/Thr Kinase Complexes with Protein Phosphatase-1 and Inhibitor-2* , 2002, The Journal of Biological Chemistry.

[39]  J. Woodgett,et al.  Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[40]  Henning Walczak,et al.  TRAIL‐R2: a novel apoptosis‐mediating receptor for TRAIL , 1997, The EMBO journal.

[41]  John Calvin Reed,et al.  Immunohistochemical analysis of in vivo patterns of Bcl-X expression. , 1994, Cancer research.

[42]  M. Pierotti,et al.  bcl-2 proto-oncogene expression in normal and neoplastic human myeloid cells. , 1992, Blood.

[43]  Jun Qin,et al.  Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin. , 2005, Molecular cell.